Diabetes Connections | Type 1 Diabetes cover art

Diabetes Connections | Type 1 Diabetes

Diabetes Connections | Type 1 Diabetes

By: Stacey Simms
Listen for free

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.Stacey Simms Media 2015-2026 Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more!

    In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more!
    May 19 2026
    It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think.. Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology. PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM. PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems. Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/-- XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It ...
    Show More Show Less
    15 mins
  • "Every trip is a learning experience" Advice from travel-loving T1D parents, Sarah Steward Holland and Nicholas Holland

    "Every trip is a learning experience" Advice from travel-loving T1D parents, Sarah Steward Holland and Nicholas Holland
    May 12 2026

    Let's talk travel!

    It's that time of year when we start getting ready for family vacations and trips big and small. Whether you're driving to the beach for a long weekend, heading to a week-long family reunion or taking that dream vacation overseas, diabetes makes everything just a little bit more complicated.

    I'm talking to Sarah Stewart Holland and Nicholas, parents of three boys, one with type 1. Nicholas has put together a great travel guide and we have a helpful and eye opening conversation about taking T1D along for the ride.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Check out the Holland's travel guide here

    Learn more about our upcoming in-person events like Moms' Night Out and Club 1921 here

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    50 mins
  • In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more!

    In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more!
    May 5 2026
    It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more. Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/ XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community. It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌​has approved the first generic ​version of ​Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028. XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its ...
    Show More Show Less
    14 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet